Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 13
Submit an article Journal homepage
266
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy

Morten Orebo HolmströmDepartment of Hematology, Zealand University Hospital, Roskilde, Denmark; ;National Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-3764-8578View further author information
ORCID Icon,
Guy W. NovotnyDepartment of Hematology, Herlev University Hospital, Herlev, Denmark; View further author information
,
Jesper PetersenDepartment of Hematology, Herlev University Hospital, Herlev, Denmark; ORCID Iconhttp://orcid.org/0000-0001-6116-5114View further author information
ORCID Icon,
Mia Aaboe-JørgensenNational Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark; View further author information
,
Hans Carl HasselbalchDepartment of Hematology, Zealand University Hospital, Roskilde, Denmark; ;Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; View further author information
,
Mads H. AndersenNational Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark; ;Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark; ORCID Iconhttp://orcid.org/0000-0002-2914-9605View further author information
ORCID Icon,
Signe Ledou NielsenDepartment of Pathology, Herlev University Hospital, Herlev, Denmark; View further author information
,
Daniel El FassiDepartment of Hematology, Herlev University Hospital, Herlev, Denmark; ;Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; ;Institute for Inflammation Research, Rigshospitalet University Hospital, Copenhagen, DenmarkORCID Iconhttp://orcid.org/0000-0001-8226-1658View further author information
ORCID Icon &
Claudia SchöllkopfDepartment of Hematology, Herlev University Hospital, Herlev, Denmark; ORCID Iconhttp://orcid.org/0000-0003-1465-506XView further author information
ORCID Icon show all
Pages 3296-3299 | Received 03 May 2019, Accepted 14 Jun 2019, Published online: 01 Jul 2019

References

  • Kralovics R, Passamonti F, Buser AAS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790.
  • Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–2390.
  • Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–2405.
  • Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379:1416–1430.
  • Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28:1472–1477.
  • Mansier O, Luque Paz D, Ianotto JC, et al. Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol. 2018;93:E84–E86.
  • Haunstrup LM, Ebbesen LH, Hansen M, et al. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation. Exp Hematol. 2018;68:62–65.
  • Usseglio F, Beaufils N, Calleja A, et al. Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential thrombocythemia. J Mol Diagn. 2017;19:92–98.
  • Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220–2228.
  • Tashkandi H, Moore EM, Tomlinson B, et al. Co-occurrence of type I CALR and two MPL mutations in patient with primary myelofibrosis. Ann Hematol. 2017;96:1417–1418.
  • Chachoua I, Pecquet C, El-Khoury M, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2016;127:1325–1335.
  • Lim KH, Chang YC, Chiang YH, et al. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish. Blood Cancer J. 2016;6:e481.
  • Li J, Prins D, Park HJ, et al. Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. Blood. 2018;131:649–661.
  • Holmström MO, Riley CH, Svane IM, et al. The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. Leukemia. 2016;30:2413–2416.
  • Holmström MO, Ahmad SM, Klausen U, et al. High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. Blood Cancer J. 2019;9:8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.